FADS2 and cancer: The results suggested that promoter methylation levels of SCD (Fig. S3A, Supplemental Digital Content, http://links.lww.com/MD/M967) and FADS2 (Fig. S3B, Supplemental Digital Content, http://links.lww.com/MD/M967) were upregulated in other age, race, individual cancer stages, nodal metastasis status, tumor history, and menopause status groups.